|
DRSC
>> Assays
>> Fly to Human
Several factors make genome-wide
screening in Drosophila a good entry-point into learning
about human biology, including study of infection, genetic
diseases, and cancer. Here we describe ways that screens
initiated in fly cells can be used to identify mammalian
genes involved in specific processes or pathways.
Why screen in fly cells?
Several features make RNAi in flies a
powerful tool for exploring human gene function,
including:
- Relatively small genome (~15,000 genes)
- Rapid and low-cost genome-wide screening as compared with an equivalent screen in mammalian cells
- Low redundancy increases the chance a given function will be identified
- Extremely well-annotated genome
- Wealth of computational and experimental data to draw from for post-analysis
- Protein-coding and non-coding RNAs well annotated and included in the screening set
- Higher chance a gene identified in the screen is associated with a function
- Significant similarity to the human genome
- Fly homologs exist for a significant fraction of human disease genes
- Numerous examples of conserved pathways in flies and humans
Has the approach proven successful?
The answer is
"Yes!"
At the bottom
of this page is a list of reference citations in which a fly
screen was done at the DRSC and the data were quickly
carried on to follow-up studies in mammalian systems.
Most
researchers take the approach to perform a screen in fly
cells first and then follow-up on mammalian homologs in
subsequent analyses. An alternative approach would be to
perform screens in fly and mammalian cells concurrently,
followed by data integration to identify gene hits common to
both screens versus those identified in one system but not
the other.
Additionally,
what you learn about assay design; high-throughput screening
and imaging; data and image analysis; and hit verification
and validation in fly cells will give you an excellent
foundation for performing mammalian cell screens in the
future.
What services are available?
Help with Assay Design
The appropriate
assay will depend on the interests of your lab group and on
available reagents such as cloned genes, markers, and
antibodies. Our expert staff can help with fly-specific
decisions, such as what cell types and expression vectors
would be appropriate for your assay.
State-of-the-Art Screening
Facility
Our staff and
state-of-the-art automated equipment make it possible for
one person from your lab group to perform a genome-wide
screen (about 8 weeks) or sub-library screen (about two
weeks) on-site at the DRSC.
Please browse
the website or contact us for more information about assay
design, reagents and screening at the DRSC.
Help with Screen Post-Analysis,
Verification and Validation
After the
screen, we will assist with data and image analysis so that
you can appropriately identify hits in your screen (expert
advice and on-line tools provided).
A number of
steps post-screening can help narrow a list of hits to a
verified list of candidates, including testing with an
independent amplicon against the same gene and testing for
rescue. Our staff can help you to plan post-screening
verification and validation steps (protocols, reagents and
on-line tools provided).
We will also
help you to identify mammalian homologs of verified gene
hits from your fly screen to help you plan next steps. If
you take the approach to perform fly and mammalian screens
concurrently, we can help you to identify genes that hit in
both screens (expert advice, bioinformatics analysis and
on-line tools provided).
References
Zhang S, Binari R, Zhou R, Perrimon N. A
Genome-wide RNAi Screen for Modifiers of Aggregates
Formation by Mutant Huntingtin in
Drosophila. Genetics. 2010 Jan 25. [Epub ahead of
print]
Sessions OM, Barrows NJ, Souza-Neto JA,
Robinson TJ, Hershey CL, Rodgers MA, Ramirez JL,
Dimopoulos G, Yang PL, Pearson JL, Garcia-Blanco MA.
Discovery of insect and human dengue virus host
factors. Nature 2009 Apr 23; 485; 1047-50.
Kwon M, Godinho SA, Chandhok NS, Ganem NJ,
Azioune A, Thery M, Pellman D. Mechanisms to suppress
multipolar divisions in cancer cells with extra
centrosomes. Genes Dev. 2008 Aug 15;22(16):2189-203.
Epub 2008 Jul 28.
Sepp KJ, Hong P, Lizarraga SB, Liu JS, Mejia
LA, Walsh CA, Perrimon N. Identification of neural outgrowth
genes using genome-wide RNAi. PLoS Genet 2008 Jul
4;4(7):e1000111.
Gandre-Babbe S and van der Bliek AM. The
Novel Tail-anchored Membrane Protein Mff Controls
Mitochondrial and Peroxisomal Fission in Mammalian
Cells. Mol Biol Cell
10.1091/mbc.E07-12-1287. epub. ahead of print March 19,
2008.
Farny NG, Hurt JA, Silver PA. Definition of
global and transcript-specific mRNA export pathways in
metazoans. Genes Dev. 2008 Jan 1;22(1):66-78.
Lu J, Ruhf ML, Perrimon N, Leder P. A
genome-wide RNA interference screen identifies putative
chromatin regulators essential for E2F repression. Proc
Natl Acad Sci U S A. 2007 May 29;104(22):9381-6.
Yi CH, Sogah DK, Boyce M, Degterev A,
Christofferson DE, Yuan J. A genome-wide RNAi screen reveals
multiple regulators of caspase activation. J Cell
Biol. 2007 Nov 19;179(4):619-26.
Gwack Y, Srikanth S, Feske S, Cruz-Guilloty
F, Oh-hora M, Neems DS, Hogan PG, Rao A. Biochemical and
functional characterization of Orai proteins. J Biol
Chem. 2007 Jun 1;282(22):16232-43. Epub 2007 Feb 9.
Vig M, Peinelt C, Beck A, Koomoa DL, Rabah
D, Koblan-Huberson M, Kraft S, Turner H, Fleig A, Penner R,
Kinet JP. CRACM1 is a plasma membrane protein essential for
store-operated Ca2+ entry. Science. 2006 May
26;312(5777):1220-3.
Gwack Y, Sharma S, Nardone J, Tanasa B, Iuga
A, Srikanth S, Okamura H, Bolton D, Feske S, Hogan PG, Rao
A. A genome-wide Drosophila RNAi screen identifies
DYRK-family kinases as regulators of
NFAT. Nature. 2006 Jun 1;441(7093):646-50.
|